335 related articles for article (PubMed ID: 27916548)
1. High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia.
Shi J; Fu H; Jia Z; He K; Fu L; Wang W
EBioMedicine; 2016 Dec; 14():55-64. PubMed ID: 27916548
[TBL] [Abstract][Full Text] [Related]
2. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
Shi JL; Fu L; Wang WD
Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of CPT1a as a prognostic marker can synergistically enhance the antileukemic activity of ABT199.
Mao S; Ling Q; Pan J; Li F; Huang S; Ye W; Wei W; Lin X; Qian Y; Wang Y; Huang X; Huang J; Wang J; Jin J
J Transl Med; 2021 Apr; 19(1):181. PubMed ID: 33926484
[TBL] [Abstract][Full Text] [Related]
4. Aberrant
Huang S; Huang Z; Chen P; Feng C
Front Oncol; 2020; 10():1648. PubMed ID: 33014825
[No Abstract] [Full Text] [Related]
5. Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemia.
Shi JL; Fu L; Ang Q; Wang GJ; Zhu J; Wang WD
Oncotarget; 2016 Jan; 7(3):2585-95. PubMed ID: 26506237
[TBL] [Abstract][Full Text] [Related]
6. Acidic leucine-rich nuclear phosphoprotein-32A expression contributes to adverse outcome in acute myeloid leukemia.
Huang S; Huang Z; Ma C; Luo L; Li YF; Wu YL; Ren Y; Feng C
Ann Transl Med; 2020 Mar; 8(6):345. PubMed ID: 32355789
[TBL] [Abstract][Full Text] [Related]
7. Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.
Fu L; Shi J; Hu K; Wang J; Wang W; Ke X
Oncotarget; 2015 Apr; 6(10):8144-54. PubMed ID: 25924238
[TBL] [Abstract][Full Text] [Related]
8. High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia.
Fu L; Fu H; Tian L; Xu K; Hu K; Wang J; Wang J; Jing H; Shi J; Ke X
Oncotarget; 2016 Mar; 7(13):15828-39. PubMed ID: 26910834
[TBL] [Abstract][Full Text] [Related]
9. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
[TBL] [Abstract][Full Text] [Related]
10. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia.
Metzeler KH; Heilmeier B; Edmaier KE; Rawat VP; Dufour A; Döhner K; Feuring-Buske M; Braess J; Spiekermann K; Büchner T; Sauerland MC; Döhner H; Hiddemann W; Bohlander SK; Schlenk RF; Bullinger L; Buske C
Blood; 2012 Sep; 120(10):2118-26. PubMed ID: 22815426
[TBL] [Abstract][Full Text] [Related]
11. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
12. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia.
Xu ZJ; Ma JC; Zhou JD; Wen XM; Yao DM; Zhang W; Ji RB; Wu DH; Tang LJ; Deng ZQ; Qian J; Lin J
J Transl Med; 2019 Mar; 17(1):102. PubMed ID: 30922328
[TBL] [Abstract][Full Text] [Related]
13. LINC00649 underexpression is an adverse prognostic marker in acute myeloid leukemia.
Guo C; Gao YY; Ju QQ; Zhang CX; Gong M; Li ZL
BMC Cancer; 2020 Sep; 20(1):841. PubMed ID: 32883226
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of carnitine palmitoyl transferase 1A-induced fatty acid oxidation suppresses cell progression in gastric cancer.
Wang L; Li C; Song Y; Yan Z
Arch Biochem Biophys; 2020 Dec; 696():108664. PubMed ID: 33157102
[TBL] [Abstract][Full Text] [Related]
15. Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias.
Ricciardi MR; Mirabilii S; Allegretti M; Licchetta R; Calarco A; Torrisi MR; Foà R; Nicolai R; Peluso G; Tafuri A
Blood; 2015 Oct; 126(16):1925-9. PubMed ID: 26276667
[TBL] [Abstract][Full Text] [Related]
16. Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Yao DM; Zhang W; Lin J; Qian J
J Cell Physiol; 2018 Jun; 233(6):4707-4714. PubMed ID: 29115660
[TBL] [Abstract][Full Text] [Related]
17. Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia.
Jinlong S; Lin F; Yonghui L; Li Y; Weidong W
PLoS One; 2015; 10(2):e0118099. PubMed ID: 25646775
[TBL] [Abstract][Full Text] [Related]
18. Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients.
Tsai CH; Yao CY; Tien FM; Tang JL; Kuo YY; Chiu YC; Lin CC; Tseng MH; Peng YL; Liu MC; Liu CW; Yao M; Lin LI; Chou WC; Chen CY; Hou HA; Tien HF
EBioMedicine; 2019 Feb; 40():240-250. PubMed ID: 30662003
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.
Kühnl A; Valk PJ; Sanders MA; Ivey A; Hills RK; Mills KI; Gale RE; Kaiser MF; Dillon R; Joannides M; Gilkes A; Haferlach T; Schnittger S; Duprez E; Linch DC; Delwel R; Löwenberg B; Baldus CD; Solomon E; Burnett AK; Grimwade D
Blood; 2015 May; 125(19):2985-94. PubMed ID: 25805812
[TBL] [Abstract][Full Text] [Related]
20. Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer.
Shao H; Mohamed EM; Xu GG; Waters M; Jing K; Ma Y; Zhang Y; Spiegel S; Idowu MO; Fang X
Oncotarget; 2016 Jan; 7(4):3832-46. PubMed ID: 26716645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
